Mr Andrew John Ninichuck, MD | |
527 Benham St, Bonne Terre, MO 63628-1205 | |
(573) 358-9119 | |
(573) 358-9489 |
Full Name | Mr Andrew John Ninichuck |
---|---|
Gender | Male |
Speciality | General Practice |
Experience | 33 Years |
Location | 527 Benham St, Bonne Terre, Missouri |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1609841956 | NPI | - | NPPES |
1609841956 | Medicaid | MO |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208D00000X | General Practice | 102387 (Missouri) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Kindred At Home | Rolla, MO | Home health agency |
Amedisys Home Health Of Missouri | Hillsboro, MO | Home health agency |
Washington County Memorial Hospital | Potosi, MO | Hospital |
Parkland Health Center | Farmington, MO | Hospital |
Parkland Health Center - Bonne Terre | Bonne terre, MO | Hospital |
Mercy Hospital Jefferson | Festus, MO | Hospital |
Entity Name | Washington County Memorial Hospital |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1194838821 PECOS PAC ID: 3476456880 Enrollment ID: O20040131000146 |
News Archive
Midgut neuroendocrine tumors are a rare type of cancer that develops in the small intestine and colon. Roughly 12,000 people are diagnosed with this disease each year. In January, the United Stated Food and Drug Administration approved Lutathera, a first-of-its-kind peptide receptor radionuclide therapy.
Precision NanoSystems, Inc. and Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the two companies have formed an exclusive collaboration focused on the discovery and development of novel lipid nanoparticles, known as small lipid nanoparticles ("sLNPs"), using microfluidics technology.
The microbes on your skin determine how attractive you are to mosquitoes, which may have important implications for malaria transmission and prevention, according to a study published Dec. 28 in the online journal PLoS ONE.
CMS on Monday announced that 325 suppliers have won contracts in the first phase of a durable medical equipment competitive bidding program for Medicare scheduled to begin on July 1, CQ HealthBeat reports (Carey, CQ HealthBeat, 5/19).
› Verified 7 days ago
Entity Name | Primary Care Of Bonne Terre Llc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1962883751 PECOS PAC ID: 4183925415 Enrollment ID: O20151210001830 |
News Archive
Midgut neuroendocrine tumors are a rare type of cancer that develops in the small intestine and colon. Roughly 12,000 people are diagnosed with this disease each year. In January, the United Stated Food and Drug Administration approved Lutathera, a first-of-its-kind peptide receptor radionuclide therapy.
Precision NanoSystems, Inc. and Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the two companies have formed an exclusive collaboration focused on the discovery and development of novel lipid nanoparticles, known as small lipid nanoparticles ("sLNPs"), using microfluidics technology.
The microbes on your skin determine how attractive you are to mosquitoes, which may have important implications for malaria transmission and prevention, according to a study published Dec. 28 in the online journal PLoS ONE.
CMS on Monday announced that 325 suppliers have won contracts in the first phase of a durable medical equipment competitive bidding program for Medicare scheduled to begin on July 1, CQ HealthBeat reports (Carey, CQ HealthBeat, 5/19).
› Verified 7 days ago
Mailing Address | Practice Location Address |
---|---|
Mr Andrew John Ninichuck, MD 527 Benham St, Bonne Terre, MO 63628-1205 Ph: (573) 358-9119 | Mr Andrew John Ninichuck, MD 527 Benham St, Bonne Terre, MO 63628-1205 Ph: (573) 358-9119 |
News Archive
Midgut neuroendocrine tumors are a rare type of cancer that develops in the small intestine and colon. Roughly 12,000 people are diagnosed with this disease each year. In January, the United Stated Food and Drug Administration approved Lutathera, a first-of-its-kind peptide receptor radionuclide therapy.
Precision NanoSystems, Inc. and Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the two companies have formed an exclusive collaboration focused on the discovery and development of novel lipid nanoparticles, known as small lipid nanoparticles ("sLNPs"), using microfluidics technology.
The microbes on your skin determine how attractive you are to mosquitoes, which may have important implications for malaria transmission and prevention, according to a study published Dec. 28 in the online journal PLoS ONE.
CMS on Monday announced that 325 suppliers have won contracts in the first phase of a durable medical equipment competitive bidding program for Medicare scheduled to begin on July 1, CQ HealthBeat reports (Carey, CQ HealthBeat, 5/19).
› Verified 7 days ago